Sanofia Ventis Korea announced on the 11th that it is conducting a partial drug cost support program for atopic dermatitis patients who administer 200mg of’Dupigent Freefield’ (ingredient name Dupilumab).
The target audience is ▲ patients who meet the requirements of Dupigent and use 200mg ▲ meet the household median income standard of 180% or less.
Dupigent is the first targeted biological drug approved for the treatment of moderate-severe atopic dermatitis in adolescents over 12 years of age and adults who are not properly controlled or recommended for these treatments as a topical treatment, and 200mg was additionally launched in Korea last October.
Dupigent 200mg is administered to atopic dermatitis patients aged 12 years or older and weighing less than 60kg, and 300mg is administered to adolescents and adults over 60kg. Currently, Dupixent health insurance benefits are for adult patients only.
This drug cost support program is a separate program conducted by Sanofi for adolescent patients who are not covered by health insurance, and is designed to contribute to improving the quality of life of patients by reducing the burden on patients’ treatment costs and helping them receive treatment at an appropriate time. .
Sanofizenzyme President Park Hee-kyung said, “I am happy that the treatment environment for adult patients has improved as the application of the special calculation for adult patients with moderate-severe atopic dermatitis has started.” In order to ensure access to treatment by people, we have launched a partial support program for the Dupigent 200mg drug fee.”